Citi Pharma (KAR:CPHL) Scaled Net Operating Assets: (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
15 GF Score
Price ₨75.08
! 1 Warning Sign
View Full Analysis

What is Citi Pharma Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Citi Pharma's operating assets for the quarter that ended in . 20 was ₨ Mil. Citi Pharma's operating liabilities for the quarter that ended in . 20 was ₨ Mil. Citi Pharma's Total Assets for the quarter that ended in . 20 was ₨ Mil. Therefore, Citi Pharma's scaled net operating assets (SNOA) for the quarter that ended in . 20 was .

Citi Pharma Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Citi Pharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma Scaled Net Operating Assets Chart

Citi Pharma Annual Data
Trend
Scaled Net Operating Assets

Citi Pharma Semi-Annual Data
Scaled Net Operating Assets

KAR:CPHL vs ZTS, UTHR, VTRS: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citi Pharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citi Pharma Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citi Pharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Citi Pharma's Scaled Net Operating Assets falls into.


KAR:CPHL
15GF Score
Citi Pharma Ltd KAR:CPHL
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citi Pharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Citi Pharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in . 20 is calculated as

Scaled Net Operating Assets (SNOA)(A: . 20 )
=(Operating Assets (A: . 20 )-Operating Liabilities (A: . 20 ))/Total Assets (A: . 20 )
=(-)/
=

where

Operating Assets(A: . 20 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
= -
=

Operating Liabilities(A: . 20 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
= - -
=

Citi Pharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in . 20 is calculated as

Scaled Net Operating Assets (SNOA)(Q: . 20 )
=(Operating Assets (Q: . 20 )-Operating Liabilities (Q: . 20 ))/Total Assets (Q: . 20 )
=(-)/
=

where

Operating Assets(Q: . 20 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
= -
=

Operating Liabilities(Q: . 20 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
= - -
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
15GF Score

Get the complete analysis for KAR:CPHL

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨75.08
Price